Drug Trial Radar · NCT06281236
A Trial of Prednisolone in Combination With SPI-62 in Participants With Polymyalgia Rheumatica (PMR)
Last checked: Nov 19, 2026Latest source record: May 16, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
1
Actual
Start
Feb 22, 2022
Primary completion
Mar 25, 2025
Study completion Apr 25, 2025
Sponsor
- Lead sponsor
- Sparrow PharmaceuticalsIndustry
- Sponsor type
- Industry
- First posted
- Feb 28, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This will be an open label phase 1b trial to characterize the pharmacodynamics and PK of prednisolone and SPI-62 when co-administered to participants with PMR. Up to 24 participants could be recruited.
Conditions
- Polymyalgia Rheumatica
Interventions
PrednisoloneDrug
Prednisolone according to the participant's pre-trial dose, symptoms and inflammatory biomarkers.
SPI-62Drug
SPI-62 administered once daily.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Erythrocyte sedimentation rateTime frame: Baseline to Day 28
- C-reactive proteinTime frame: Baseline to Day 28
- Plasma fibrinogenTime frame: Baseline to Day 28
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
Emovis Gmbh
Berlin, Germany
Klinische Forschung Hannover Mitte GmbH/Pratia
Hanover, Germany
Universitätsmedizin der Johannes Gutenburg Universität Mainz
Mainz, Germany
Klinikum der Universität München
München, Germany
Klinische Forschung Schwerin GmbH/Pratia
Schwerin, Germany
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.